基于“瘀毒”理论探讨线粒体自噬与特发性肺纤维化的相关性
1.山东中医药大学,山东 济南 250355;
2.山东中医药大学附属医院,山东 济南 250014
收稿日期: 2025-12-30
修回日期: 2026-02-12
录用日期: 2026-04-20
网络出版日期: 2026-10-27
基金资助
国家自然科学基金项目(82305146);第六批全国名老中医药专家传承工作项目(2022gzs-05);中医药联合基金项目(ZR2021LZY031);山东省中医药科技面上项目(M20241816);山东省重点研发计划(2024CXPT015);山东省青年科技人才托举工程资助(SDAST2024QTB006);筑峰人才(zfrc-202403)
Correlation between Mitochondrial Autophagy and Idiopathic Pulmonary Fibrosis Based on the Theory of "Stagnant Toxin"
Received date: 2025-12-30
Revised date: 2026-02-12
Accepted date: 2026-04-20
Online published: 2026-10-27
特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)是一种病因未明、进行性加重的慢性间质性肺疾病,以不可逆的肺实质瘢痕形成和肺功能进行性丧失为特征。“瘀毒”理论是中医学阐释疑难重症病机的重要学说,强调“瘀血”与“毒邪”相互搏结、化生为病,具有胶结缠绵、骤发多变的致病特点。线粒体自噬作为细胞选择性清除受损线粒体的关键机制,其失衡导致功能障碍线粒体累积、活性氧爆发及促纤维化因子释放,深入参与IPF的肺泡上皮损伤与成纤维细胞异常活化进程。本研究基于“瘀毒”理论探讨线粒体自噬与IPF的相关性,认为线粒体自噬失衡所呈现的毒性损伤与致瘀效应体现了IPF“瘀毒”致病的病机本质,从“瘀”与线粒体代谢障碍、“毒”与自噬失衡毒性效应两方面阐释“瘀毒”病机与线粒体自噬的内在关联,提出临床可运用活血通络以改善线粒体代谢障碍,清热解毒以清除自噬失衡代谢产物。本研究旨在为中西医结合诊治IPF提供新的理论视角与治疗思路。
王亦凡
.
基于“瘀毒”理论探讨线粒体自噬与特发性肺纤维化的相关性
Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease of unknown etiology characterized by progressive deterioration, irreversible pulmonary parenchymal scarring, and progressive loss of lung function. The "Yudu" (Stagnant-Toxin) theory in Traditional Chinese Medicine (TCM) elucidates the pathogenesis of severe and complex diseases, emphasizing the pathological mechanism where "stagnant blood" and "toxic pathogens" interact to form diseases, exhibiting adhesive, persistent, and rapidly evolving characteristics. Mitochondrial autophagy, as a key mechanism for selective clearance of damaged mitochondria, leads to mitochondrial dysfunction, accumulation of reactive oxygen species (ROS), and fibrotic factor release, deeply involved in alveolar epithelial injury and abnormal fibroblast proliferation in IPF. Based on the "Yudu" theory, this study explores the correlation between mitochondrial autophagy and IPF, proposing that the toxic damage and stasis-inducing effects of mitochondrial autophagy imbalance reflect the essential pathogenic mechanism of "Yudu" in IPF. The study interprets the relationship between "Yudu" pathogenesis and mitochondrial autophagy from two aspects: "stagnation" and mitochondrial metabolic disorders, and "toxicity" and autophagy imbalance. Clinical approaches include promoting blood circulation to improve mitochondrial metabolic disorders and clearing heat-toxins to eliminate autophagy-related metabolites. This research aims to provide new theoretical perspectives and therapeutic strategies for integrated TCM-Western medicine treatment of IPF.
[1] 于娜,周家为,李霞,等.成人特发性肺纤维化(更新)和进行性肺纤维化临床实践指南(2022版)解读[J].中国现代医学杂志,2023,33(14):1-8.
[2] Luppi F, Kalluri M, Faverio P, et al. Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management[J].Respir Res, 2021,22(1):109.
[3] Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis[J].Lancet, 2017,389(10082):1941-1952.
[4] Koudstaal T, Wijsenbeek MS. Idiopathic pulmonary fibrosis[J].Presse Med, 2023,52(3):104166.
[5] 谭诗旖,陈适.线粒体自噬与肺部疾病的研究进展[J].基础医学与临床,2020,40(6):842-846.
[6] 徐菁菁,田燕歌,梅雪,等.线粒体质量控制在呼吸系统疾病中的研究进展[J].中国比较医学杂志,2024,34(6):161-171.
[7] 柳金英,张惠敏,田蕾,等.“瘀毒”致心力衰竭心肌纤维化理论依据初探[J].中华中医药杂志,2018,33(9):4027-4030.
[8] 钟霞,焦华琛,李运伦,等.瘀毒概念探微[J].中华中医药杂志,2019,34(6):2377-2380.
[9] Zank DC, Bueno M, Mora AL, et al. Idiopathic pulmonary fibrosis: aging, mitochondrial dysfunction, and cellular bioenergetics[J].Front Med (Lausanne), 2018,5:10.
[10] 钟霞,焦华琛,李运伦,等.毒邪实质刍议[J].辽宁中医药大学学报,2020,22(5):88-91.
[11] 张翌蕾,崔应麟.毒邪学说研究进展[J].中华中医药杂志,2020,35(10):5074-5076.
[12] 邹林蓁,李运伦.从“瘀毒”论治心系疾病进展[J].中医药学报,2018,46(3):125-129.
[13] 张伟.“瘀毒”理论指导下不同肺系疾病诊疗思路[J].山东中医杂志,2025,44(1):18-23,17.
[14] 景传庆,孔慧,张伟,等.基于“虚瘀毒”探析特发性肺纤维化[J].山东中医杂志,2025,44(7):729-733.
[15] 于睿智,庞立健,王天娇,等.从虚、毒、痰、瘀辨治特发性肺纤维化[J].中华中医药杂志,2022,37(10):5815-5818.
[16] 姜瑞雪,黄密,谢有琼.雾霾伤肺的病因病机及其与肺络的关系探析[J].辽宁中医杂志,2020,47(11):85-86.
[17] 刘骅漫,贾新华,田丽,等.从“毒损肺络”理论探讨特发性肺纤维化肌成纤维细胞活化机制[J].中华中医药杂志,2022,37(2):646-649.
[18] 刘勇明,吕晓东,庞立健,等.从瘀论治特发性肺纤维化研究进展[J].中华中医药学刊,2025,43(7):108-113.
[19] Lemasters JJ. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging[J].Rejuvenation Res, 2005,8(1):3-5.
[20] 李美玲,徐喜媛.从基础到临床:急性呼吸窘迫综合征中线粒体自噬的研究现状[J/OL].中国生物化学与分子生物学报,1-14[2025-10-27].https://doi.org/10.13865/j.cnki.cjbmb.2025.08.1177.
[21] Bueno M, Lai YC, Romero Y, et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis[J].J Clin Invest. 2015,125(2):521-538.
[22] Kobayashi K, Araya J, Minagawa S, et al. Involvement of PARK2-mediated mitophagy in idiopathic pulmonary fibrosis pathogenesis[J].J Immunol, 2016,197(2):504-516.
[23] Sosulski ML, Gongora R, Danchuk S, et al. Deregulation of selective autophagy during aging and pulmonary fibrosis: the role of TGFβ1[J].Aging Cell, 2015,14(5):774-783.
[24] Kurita Y, Araya J, Minagawa S, et al. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy[J].Respir Res, 2017,18(1):114.
[25] Larson-Casey JL, Deshane JS, Ryan AJ, et al. Macrophage Akt1 kinase-mediated mitophagy modulates apoptosis resistance and pulmonary fibrosis[J].Immunity, 2016,44(3):582-596.
[26] Meng Ying, Pan Miaoxiao, Zheng Bojun, et al. Autophagy attenuates angiotensin Ⅱ-induced pulmonary fibrosis by inhibiting redox imbalance-mediated NOD-like receptor family pyrin domain containing 3 inflammasome activation[J].Antioxid Redox Signal, 2019,30(4):520-541.
[27] Xu Mengmeng, Wang Xiaohui, Xu Lu, et al. Chronic lung inflammation and pulmonary fibrosis after multiple intranasal instillation of PM2.5 in mice[J].Environ Toxicol, 2021,36(7):1434-1446.
[28] 王怡然,张伟.从气虚血瘀与血管新生相关性论治特发性肺纤维化[J].山东中医杂志,2024,43(4):353-356.
[29] 刘勇明,吕晓东,庞立健,等.基于“肺虚络瘀”病机观探讨血小板活化与特发性肺纤维化的作用机制[J].中华中医药杂志,2025,40(2):569-574.
[30] 熊梦清,赵杨,胡克.特发性肺纤维化中的线粒体质量控制[J].临床肺科杂志,2022,27(3):445-449.
[31] 冯同,高瑕,王波,等.线粒体质量控制失调与特发性肺纤维化的关系研究进展[J].解放军医学杂志,2022,47(1):78-83.
[32] 于睿智,王天娇,臧凝子,等.络病理论指导下特发性肺纤维化急性加重因机证治刍议[J].中华中医药杂志,2024,39(6):2823-2826.
[33] 范锐,田梅,张伟.张伟应用补阳还五汤治疗气虚血瘀型肺纤维化经验[J].山东中医杂志,2025,44(8):835-839.
[34] 王哲,汪国梁,王梓仪,等.基于FUNDC1介导的线粒体自噬探究黄芪-丹参对心肌缺血再灌注损伤大鼠的保护作用[J].中国实验方剂学杂志,2025,31(14):31-39.
[35] 柯诗文.温肺化纤汤对氧化应激环境下小鼠肺间充质干细胞线粒体质量的调控及分子机制初探[D].南昌:江西中医药大学,2020.
[36] 王腊,江桂通,王文佳,等.黄连解毒汤激活自噬减轻脓毒症大鼠急性肺损伤[J].时珍国医国药,2023,34(9):2080-2083.
[37] 赵滋苗,秦金燕,臧倩,等.黄连解毒汤靶向PINK1/Parkin通路调控线粒体自噬缓解脓毒症心肌损伤的机制研究[J].浙江中西医结合杂志,2025,35(10):901-908,914.
[38] 李耀杨,金旭东,高玉峰.黄芩素通过miR-141-3p/sirt7介导的线粒体自噬发挥帕金森病神经保护作用的机制研究[J].脑与神经疾病杂志,2024,32(5):290-296.
[39] 刘静静.连翘酯苷A调控PINK1/Parkin通路介导的线粒体自噬缓解LPS诱导的乳房炎[D].郑州:河南农业大学,2024.
/
| 〈 |
|
〉 |